Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $44.1252W HIGH $78.00
Volume
1.47 M
Value Traded
64.01 M
Short % Float
21.24%
-6.89%Week
+2.16%1 Month
+5.45%3 Month
-2.63%6 Month
-56.94%5 Year
+235.73%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
5.16 B
EPS (TTM)
-4.67
P/E Ratio
-
Ent. Value
3.38 B
Total Shares
96.69 M
Float Shares
89.77 M
Insiders
7.16%
Institutions
73.13%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
CRSP Catalyst Timeline
Dated clinical, regulatory and corporate events for CRISPR Therapeutics AG
Catalyst Timeline
Dated clinical, regulatory & corporate events for CRISPR Therapeutics AG
546Total events
14Upcoming
119Tier-1 (high impact)
2016 to 2026Coverage
Upcoming catalysts 2
Event history 50
▲Oral PresentationCTX310Presentation
Late-breaking presentation of Phase 1a durability data for CTX310 at ESC Congress 2026
dyslipidemiassource ↗
▲PublicationCTX310Presentation
Publication of CTX310 Phase 1a durability data in The New England Journal of Medicine
dyslipidemiassource ↗
▲FDA ApprovalCASGEVYApprovedFDA Decision
FDA approved CASGEVY for children as young as 2 years with SCD or TDT
sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT) in children 2 years and oldersource ↗
●NDA SubmissionCASGEVYApprovedRegulatory Filing
Regulatory submissions completed for CASGEVY in KSA and UK for children 5-11 years
SCD or TDT in children 5 to 11 yearssource ↗
▲Trial InitiationCTX340Trial
Initiated Phase 1 clinical trial for CTX340 in refractory hypertension
refractory hypertensionsource ↗
▲Trial InitiationCTX460Trial
Initiated Phase 1 clinical trial for CTX460 in AATD
alpha-1 antitrypsin deficiency (AATD)source ↗
▲Trial Initiationzugo-celTrial
Initiated third Phase 1 trial of zugo-cel in autoimmune neurologic diseases
autoimmune neurologic diseases (PMS, NMOSD, MOGAD, AIE, SPS)source ↗
●Enrollment Updatezugo-celTrial
Enrollment continues across zugo-cel autoimmune program
autoimmune diseases (SSc, IIM, SLE, ITP, wAIHA)source ↗
▲Preclinical PoCCTX213Preclinical
CTX213 demonstrated compelling preclinical efficacy; progressing toward clinic
Type 1 diabetessource ↗
●IND Enabling CompleteCTX321Preclinical
CTX321 progressing through IND/CTA-enabling studies
elevated lipoprotein(a)source ↗
▲Trial InitiationCTX460Trial
Initiation of clinical trial for CTX460 expected in mid-2026
alpha-1 antitrypsin deficiency (AATD)source ↗
▲Other Regulator MilestoneCASGEVYApprovedEx-US Regulatory
Vertex secured reimbursement for CASGEVY in Germany for patients 12+ years
SCD or TDT in children 5-11 yearssource ↗
▲Product LaunchCASGEVYApprovedPost-Market
Vertex secured reimbursement for CASGEVY in Germany
SCD or TDT in patients 12 years and oldersource ↗
◆Oral PresentationPresentation
Presentation at Bank of America Securities 2026 Global Healthcare Conference
▲FDA Filing AcceptedCASGEVYApprovedRegulatory Filing
Vertex completed U.S. regulatory submission for CASGEVY in children ages 5 to 11
sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT) in children ages 5 to 11source ↗
▲IND ClearanceCTX310IND
FDA clearance of IND for CTX310 supporting expansion into U.S.
severe hypertriglyceridemia (sHTG) and refractory hypercholesterolemiasource ↗
▲IND Clearancezugo-celIND
FDA cleared IND for third Phase 1 trial of zugo-cel in autoimmune neurologic diseases
autoimmune neurologic diseases (PMS, NMOSD, MOGAD, AIE, SPS)source ↗
▲Trial Initiationzugo-celTrial
Phase 1 trial of zugo-cel in autoimmune neurologic diseases initiated
autoimmune neurologic diseasessource ↗
▲REMS ModifiedCASGEVYApprovedPost-Market
Vertex secured reimbursement for CASGEVY in Germany for patients 12+ years
SCD or TDTsource ↗
◆Oral PresentationPresentation
CRISPR Therapeutics management to present at 25th Annual Needham Virtual Healthcare Conference
▲Trial InitiationCTX460Trial
Initiated Phase 1 clinical trial for CTX460
alpha-1 antitrypsin deficiency (AATD)source ↗
▲Trial InitiationCTX340Trial
Initiated Phase 1 clinical trial for CTX340
refractory hypertensionsource ↗
▲Trial Initiationzugo-celTrial
Initiated third Phase 1 trial of zugo-cel in autoimmune neurologic diseases
autoimmune neurologic diseases (PMS, NMOSD, MOGAD, AIE, SPS)source ↗
●Enrollment Updatezugo-celTrial
Enrollment ongoing across zugo-cel autoimmune basket trials
autoimmune diseases (SSc, IIM, SLE, ITP, wAIHA)source ↗
●FDA Filing AcceptedCASGEVYApprovedRegulatory Filing
Regulatory submissions completed for CASGEVY in KSA and UK for children 5-11
SCD or TDT in children 5 to 11 yearssource ↗
▼Equity OfferingCorporate
Announced proposed $350M convertible senior notes offering due 2031
▼Equity OfferingCorporate
Issued convertible senior notes in March 2026, net proceeds $585.4M
▲Quarterly UpdateCorporate
Starting 2026 with strong balance sheet of approximately $2 billion in cash, cash equivalents, and marketable securities
◆Topline ReadoutCTX320Clinical Data
Data update for CTX320 expected in first half of 2026
elevated lipoprotein(a)source ↗
◆Trial InitiationCTX340Trial
Clinical trial initiation expected for CTX340 in H1 2026
refractory hypertensionsource ↗
▲Partnership / LicenseCorporate
Vertex secured reimbursed access for CASGEVY in Scotland for SCD patients
▲Quarterly UpdateCASGEVYApprovedCorporate
CASGEVY Q4 2025 revenue $54M, full year $116M; 64 patients infused in 2025
sickle cell disease, transfusion-dependent beta thalassemiasource ↗
▲Trial InitiationCTX340Trial
Expects to initiate clinical trial for CTX340 in second half of 2025
refractory hypertensionsource ↗
▲Trial InitiationCTX450Trial
Expects to initiate clinical trial for CTX450 in second half of 2025
acute hepatic porphyria (AHP)source ↗
▲Trial Initiationzugo-celTrial
Phase 1 basket trial initiated in ITP and wAIHA
refractory primary immune thrombocytopenic purpura (ITP) and warm autoimmune hemolytic anemia (wAIHA)source ↗
▲Partnership / Licensezugo-celCorporate
Collaboration and clinical supply agreement with Lilly to evaluate zugo-cel with pirtobrutinib
aggressive B-cell lymphomassource ↗
▲Topline Readoutzugo-celClinical Data
Preliminary clinical data from Phase 1 autoimmune basket trial
autoimmune rheumatologic diseases (SLE, SSc, inflammatory myositis)source ↗
◆Oral Presentationexa-celFiledPresentation
Initial data from pediatric Phase 3 studies to be presented at ASH annual meeting
sickle cell disease and transfusion-dependent beta thalassemiasource ↗
▲Oral PresentationCASGEVYApprovedPresentation
Positive pediatric data from pivotal studies presented at ASH 2025
sickle cell disease, transfusion-dependent beta thalassemiasource ↗
Past FDA Catalysts and PDUFA Decisions
How CRSP actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-08-28 | CTX310 | Phase 1a data readout | Phase 1a |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
C51 / 100
Pipeline Score
$799M
Pipeline Value
$58M
Commercial Value
Richly Valued
Valuation Signal
5
Drugs Scored
0.2x
rNPV / MCap
Top 16%
Small Cap(rank 106 of 660)
Percentile Rank
CRISPR Therapeutics AG carries a moderate pipeline score (51/100), with $1.2B risk-adjusted pipeline value, led by CTX112 in Progressive Multiple Sclerosis (PMS) (Phase 1), across $58B in total addressable markets.
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-K and 10-Q), to Jun 2026) Revenue $13.4M x 4.4 = $58M
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| CTX112 Monoclonal antibodyNCT07549698 | Warm Autoimmune Hemolytic Anemia (WAIHA) | Phase 1 | RECRUITING | 60 | Dec 1, 2033 |
Clinical Trial Results
Readouts, endpoints and source filings for every CRSP program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| zugocaptagene geleucel | autoimmune diseases and hematologic malignancies | Phase 1 | 2025-12-22 | deep B-cell depletion sustained for at least 28 days; significant clinical improvement in patients dosed at the 100 million cell dose; first systemic lupus erythematosus (SLE) patient achieving Definitions of Remission in SLE (DORIS) remission through Month 6; overall response rate (ORR) of 90% (9/10); complete response rate (CRR) of 70% (7/10); 67% (2/3) of patients in complete response (CR) after one year on study in relapsed or refractory (R/R) large B-cell lymphoma (LBCL)Read More | CRISPR Therapeutics Provides Broad Update on Zugocaptagene Geleucel (Zugo-cel; formerly CTX112™) in Autoimmune Diseases and Hematologic MalignanciesRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| KASINGER JAMES R.Officer (General Counsel and Secretary) | Option | 1,990 96,774 held | $13.62 | 10/06/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in CRSP
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| EcoR1 Capital, LLC | 3.7 % (32.1 %) | 75.77 M | 1.39 M |
CRSP Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2027-01-15 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How CRSP ranks across every disease it competes in
Competitive Position is a premium feature
See how CRSP ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialCRSP News
CRSP▲ +7.3%today
CRISPR Therapeutics to Present Late-Breaking Data at the American Heart Association (AHA) Scientific Sessions 2026
CRISPR Therapeutics announced that it will present late-breaking data from its Phase 1b trial of CTX310, a CRISPR/Cas9 gene editing therapy targeting ANGPTL3 for severe hypertriglyceridemia. The presentation is scheduled for November 9, 2026, at the American Heart Association Scientific Sessions. This event highlights the company's advancements in gene-based therapies and its commitment to addressing serious health conditions.
Read more →CRSPCRISPR Therapeutics to Present Clinical Data on Zugocabtagene Geleucel (Zugo-cel) in Autoimmune Disease at the American College of Rheumatology (ACR) Convergence 2026
CRISPR Therapeutics announced a poster presentation of Phase 1 clinical data for its gene-edited CAR T cell therapy, zugocabtagene geleucel, at the ACR Convergence 2026. The therapy targets CD19 and is being evaluated for various autoimmune diseases. The presentation is scheduled for November 8, 2026, showcasing the company's advancements in gene-based medicines.
Read more →CRSPCRISPR Therapeutics to Present at the Morgan Stanley 24th Annual Global Healthcare Conference
CRISPR Therapeutics will present at the Morgan Stanley 24th Annual Global Healthcare Conference on September 14, 2026. The presentation will feature members of the senior management team and will be available via live webcast. The company is recognized for its advancements in gene-based therapies, including the approval of CASGEVY® for sickle cell disease.
Read more →CRSPCRISPR Therapeutics Presents Phase 1a Data for CTX310® Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and LDL Lowering at ESC Congress 2026
CRISPR Therapeutics presented Phase 1a data for CTX310 at the ESC Congress 2026, showing significant reductions in ANGPTL3, triglycerides, and LDL cholesterol. The treatment was well tolerated with no serious adverse events reported. These findings suggest that a single infusion of CTX310 could provide long-lasting lipid lowering effects, supporting its advancement into Phase 1b trials.
Read more →CRSP▲ +7.1%on this news
CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results
CRISPR Therapeutics reported strong financial results for Q2 2026, highlighting significant growth in revenue driven by CASGEVY, which is now approved for children aged 2 and older. The company initiated several Phase 1 clinical trials for new therapies, including CTX340 and CTX460. Despite a net loss of $91.2 million, CRISPR maintains a robust cash position of over $2.36 billion, positioning it well for future milestones.
Read more →CRSP▲ +5.3%on this news
CRISPR Therapeutics to Participate in Upcoming Investor Conferences
CRISPR Therapeutics announced participation in several investor conferences in June 2026, including the Jefferies Global Healthcare Conference and Goldman Sachs' Global Healthcare Conference. The company continues to lead in gene-based medicine development, highlighted by its recent approval of the first CRISPR-based therapy for sickle cell disease. Live webcasts of the events will be available on their website.
Read more →CRSP▲ +5.2%on this news
CRISPR Therapeutics to Present at the Bank of America Securities 2026 Global Healthcare Conference
CRISPR Therapeutics announced that its senior management will present at the Bank of America Securities 2026 Global Healthcare Conference on May 12, 2026. The presentation will include a live webcast, which will be available on the company's website. CRISPR Therapeutics is known for its pioneering work in gene editing and has a diverse pipeline of therapies.
Read more →CRSPCRISPR Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results
CRISPR Therapeutics announced its Q1 2026 financial results, highlighting strong revenue from CASGEVY and advancements in its gene editing pipeline. The company expanded its treatment indications and received FDA clearance for pediatric use of CASGEVY. Despite a net loss of $122.9 million, CRISPR remains optimistic about its future milestones and market potential.
Read more →CRSPCRISPR Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference
CRISPR Therapeutics will present at the 25th Annual Needham Virtual Healthcare Conference on April 13, 2026. The presentation will feature members of the senior management team and will be available via a live webcast. The company is recognized for its pioneering work in gene-based medicines, including the approval of the first CRISPR therapy for sickle cell disease.
Read more →CRSP▼ -5.4%on this news
CRISPR Therapeutics Prices Upsized Convertible Senior Notes Offering
CRISPR Therapeutics has priced $550 million in convertible senior notes due 2031, up from a previously announced $350 million. The offering is expected to close on March 16, 2026, and will provide net proceeds for general corporate purposes. The notes feature a coupon rate of 1.7308% after accounting for Swiss tax withholding.
Read more →CRSP▼ -10.2%on this newsshared move
CRISPR Therapeutics Announces Proposed Convertible Senior Notes Offering
CRISPR Therapeutics has announced a proposed offering of $350 million in convertible senior notes due 2031, intended for qualified institutional buyers under Rule 144A. The offering includes an option for purchasers to acquire an additional $52.5 million of notes. Proceeds from the offering are aimed at general corporate purposes, although the specific interest rate and terms remain to be finalized. Investors may face uncertainties as the offering's success hinges on market conditions.
Read more →CRSPCRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results ZUG, Switzerland and BOSTON
CRISPR Therapeutics announced its financial results for Q4 and the full year 2025, highlighting significant progress in various clinical and preclinical programs. The revenue from CASGEVY reached $116 million for the year, with notable increases in patient initiation rates. Encouraging data from pediatric studies of CASGEVY were presented at the ASH annual meeting, supporting future regulatory submissions expected in 2026. Furthermore, the company's strong cash position enhances its ability to support ongoing and future development activities.
Read more →CRSPCRISPR Therapeutics Highlights Strategic Priorities and Anticipated 2026 Milestones
CRISPR Therapeutics has outlined its strategic priorities and key milestones for 2026, emphasizing a robust portfolio in gene editing and siRNA therapies. The company is well-positioned with a strong financial foundation and promising clinical data, particularly for its lead programs like CASGEVY and CTX310. Anticipated advancements in various therapeutic areas, including cardiovascular and autoimmune diseases, are expected to drive growth.
Read more →CRSPCRISPR Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
CRISPR Therapeutics will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026. The presentation will feature insights from the senior management team and will be available via live webcast. The company is recognized for its pioneering work in gene editing and has made significant advancements, including the approval of the first CRISPR-based therapy.
Read more →CRSPCRISPR Therapeutics Provides Broad Update on Zugocaptagene Geleucel (Zugo-cel; formerly CTX112™) in Autoimmune Diseases and Hematologic Malignancies
CRISPR Therapeutics has provided updates on zugocaptagene geleucel (zugo-cel), showing promising results in autoimmune diseases and hematologic malignancies. Initial data indicates deep B-cell depletion and clinical improvement in patients with systemic lupus erythematosus. A Phase 1 trial has been initiated for additional autoimmune conditions, and a collaboration with Lilly aims to evaluate zugo-cel in aggressive B-cell lymphomas.
Read more →CRSPCRISPR Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results
CRISPR Therapeutics reported strong progress in its third quarter 2025 results, highlighting positive Phase 1 data for CTX310 and significant momentum for CASGEVY, with nearly 300 patient referrals. The company completed enrollment in two global Phase 3 studies for exa-cel and is advancing its pipeline, including ongoing clinical trials for CTX112 and SRSD107. With a robust financial position, CRISPR is well-positioned for future growth.
Read more →CRSPCRISPR Therapeutics Announces Positive Phase 1 Clinical Data for CTX310® Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and Lipid Lowering
CRISPR Therapeutics announced positive Phase 1 clinical data for CTX310, showing significant reductions in ANGPTL3, triglycerides, and LDL cholesterol. The treatment was well tolerated, with no serious adverse events reported. These findings suggest CTX310 could offer a transformative approach for patients with severe dyslipidemia, advancing into Phase 1b trials.
Read more →CRSPCRISPR Therapeutics Presents New Preclinical Data for CTX460™ Demonstrating In Vivo Gene Correction of Alpha-1 Antitrypsin Deficiency (AATD) Utilizing Novel SyNTase™ Editing Platform
CRISPR Therapeutics presented promising preclinical data for CTX460, a novel gene editing candidate targeting Alpha-1 Antitrypsin Deficiency (AATD), at the ESGCT 2025 Annual Congress. The data indicated over 90% mRNA correction and a significant increase in AAT levels. CTX460 is expected to enter clinical trials in mid-2026, marking a potential breakthrough in treating AATD.
Read more →CRSPCRISPR Therapeutics to Present Preclinical Data on Alpha-1 Antitrypsin Deficiency (AATD) Utilizing Novel SyNTase Gene Editing Technology at the European Society of Gene and Cell Therapy (ESGCT) 2025 Annual Congress
CRISPR Therapeutics announced the acceptance of an abstract for an oral presentation at the ESGCT 2025 Annual Congress. The presentation will showcase their SyNTase gene editing technology, which demonstrated high efficiency in correcting Alpha-1 Antitrypsin Deficiency (AATD) with minimal off-target effects. The results indicate a promising potential for a single-dose treatment for this rare genetic disorder.
Read more →CRSPCRISPR Therapeutics and Sirius Therapeutics Announce First Patient Dosed in Phase 2 Trial of SRSD107 for Thromboembolic Disorders in Europe
CRISPR Therapeutics and Sirius Therapeutics have initiated a Phase 2 clinical trial for SRSD107, a long-acting Factor XI siRNA aimed at preventing venous thromboembolism in patients undergoing total knee arthroplasty. The trial's first patient has been dosed, marking a significant milestone. SRSD107 aims to provide a safer alternative to existing anticoagulants by minimizing bleeding risks while effectively managing thrombotic conditions.
Read more →About CRISPR Therapeutics AG
HeadquartersBAARERSTRASSE 14, ZUG
BIOPHARMAWATCH ELITE PLUS
Trade the next CRSP catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime